Published: Sept 4, 2018 5:52 p.m. ET Tilray and Cronos shares hit fresh records despite Citron short bets Marijuana-related stocks rampaged higher Tuesday, after Cronos Group Inc. detailed an agreement that seeks to extract key compounds from cannabis for medicinal purposes. Canadian cannabis company Cronos

CRON, +12.85%

 announced what it called a “landmark partnership” with Boston biotech Ginkgo Bioworks Inc. on Tuesday morning that will seek to produce specific cannabinoids at scale. Cannabinoids are specific molecules in marijuana that can produce effects in the human body, with the most commonly known subclasses being Tetrahydrocannabinol, or THC, and cannabidiol, or CBD. Some cannabinoids that are found only in very small quantities in marijuana are thought to be potentially beneficial to a range of illnesses, but producing enough to test those uses is difficult. Pot stocks fly even higher after Cronos details ‘landmark partnership’

thumbnail courtesy of